Evidence map›Paper›PMID 27165276›Full record

ArticleScientific reports2016

Aquaporin-3 potentiates allergic airway inflammation in ovalbumin-induced murine asthma.

Kohei Ikezoe, Toru Oga, Tetsuya Honda, Mariko Hara-Chikuma, Xiaojun Ma, Tatsuaki Tsuruyama, Kazuko Uno, Jun-Ichi Fuchikami, Kiminobu Tanizawa, Tomohiro Handa and 5 more

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed
1.6field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 35 citations in OpenAlex.

  1. Aquaporins: a novel perspective in the treatment of lung diseases.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2025
    Review
  2. Aquaporins in Allergic Response: A New Player.Clinical reviews in allergy & immunology · 2025
    Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Aquaporins: Potential Targets in Inflammatory Diseases.The Eurasian journal of medicine · 2023
    Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 6 institutions in 2 countries.

Kohei IkezoeDepartment of Respiratory Medicine, Kyoto University Graduate School of Medicine, Sakyo-ku, Kyoto 606-8507, Japan.
Toru OgaDepartment of Respiratory Care and Sleep Control Medicine, Kyoto University Graduate School of Medicine, Sakyo-ku, Kyoto 606-8507, Japan.
Tetsuya HondaDepartment of Dermatology, Kyoto University Graduate School of Medicine, Sakyo-ku, Kyoto 606-8507, Japan.
Mariko Hara-ChikumaDepartment of Dermatology, Kyoto University Graduate School of Medicine, Sakyo-ku, Kyoto 606-8507, Japan.
Xiaojun MaCore Research for Evolutional Science and Technology (CREST) Laboratory, Medical Innovation Center, Kyoto University Graduate School of Medicine, Sakyo-ku, Kyoto 606-8501, Japan.
Tatsuaki TsuruyamaCenter for anatomical, forensic and pathology research, Kyoto University Hospital, Sakyo-ku, Kyoto 606-8501, Japan.
Kazuko UnoLouis Pasteur Center for Medical Research, Sakyo-ku, Kyoto 606-8225, Japan.
Jun-Ichi FuchikamiBioresearch Center, CMIC Pharma Science Co., Ltd., Hokuto-shi, Yamanashi 408-0044, Japan.
Kiminobu TanizawaDepartment of Respiratory Care and Sleep Control Medicine, Kyoto University Graduate School of Medicine, Sakyo-ku, Kyoto 606-8507, Japan.
Tomohiro HandaDepartment of Respiratory Medicine, Kyoto University Graduate School of Medicine, Sakyo-ku, Kyoto 606-8507, Japan.
Yoshio TaguchiDepartment of Respiratory Medicine, Tenri Hospital, Tenri-shi, Nara 632-8552, Japan.
Alan S VerkmanDepartments of Medicine and Physiology, University of California, San Francisco, CA 94143, USA.
Shuh NarumiyaCenter for Innovation in Immunoregulative Technology and Therapeutics (AK project), Kyoto University Graduate School of Medicine, Sakyo-ku, Kyoto 606-8501, Japan.
Michiaki MishimaDepartment of Respiratory Medicine, Kyoto University Graduate School of Medicine, Sakyo-ku, Kyoto 606-8507, Japan.
Kazuo ChinDepartment of Respiratory Care and Sleep Control Medicine, Kyoto University Graduate School of Medicine, Sakyo-ku, Kyoto 606-8507, Japan.
Kyoto University · JPKyoto University Hospital · JPLouis Pasteur Center for Medical Research · JPLTT Bio-Pharma (Japan) · JPTenri Hospital · JPUniversity of California, San Francisco · US

Funding

MECHANISMS OF WATER TRANSPORT IN RENAL EPITHELIAR37DK035124 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI VERKMAN, ALAN S · 1999 to 2008
$4.2M
WATER AND NON-ELECTROLYTE TRANSPORT IN RENAL VESICLESR01DK035124 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI VERKMAN, ALAN S · 1986 to 2014
$1.4M
NIDDK NIH HHS R01 DK035124NIDDK NIH HHS R37 DK035124
6 · The paper itself

Abstract

Oxidative stress plays a pivotal role in the pathogenesis of asthma. Aquaporin-3 (AQP3) is a small transmembrane water/glycerol channel that may facilitate the membrane uptake of hydrogen peroxide (H2O2). Here we report that AQP3 potentiates ovalbumin (OVA)-induced murine asthma by mediating both chemokine production from alveolar macrophages and T cell trafficking. AQP3 deficient (AQP3(-/-)) mice exhibited significantly reduced airway inflammation compared to wild-type mice. Adoptive transfer experiments showed reduced airway eosinophilic inflammation in mice receiving OVA-sensitized splenocytes from AQP3(-/-) mice compared with wild-type mice after OVA challenge, consistently with fewer CD4(+) T cells from AQP3(-/-) mice migrating to the lung than from wild-type mice. Additionally, in vivo and vitro experiments indicated that AQP3 induced the production of some chemokines such as CCL24 and CCL22 through regulating the amount of cellular H2O2 in M2 polarized alveolar macrophages. These results imply a critical role of AQP3 in asthma, and AQP3 may be a novel therapeutic target.

Indexed as

AnimalsAquaporin 3AsthmaBronchoalveolar Lavage FluidCD4-Positive T-LymphocytesCell CountCell Membrane PermeabilityChemokinesGene Expression RegulationHydrogen PeroxideHypersensitivityLymph NodesMacrophages, AlveolarMice, Inbred C57BLOvalbuminPneumoniaAquaporin 3ChemokinesHydrogen PeroxideOvalbuminRNA, Messenger

Identifiers

PMID27165276
PMCPMC4863152
OpenAlexW2365619001

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.